Myelofibrosis treatment depends on where you fall on the risk spectrum and which symptoms dominate your daily life. There is no single treatment path. Instead, the approach starts with determining your risk category, then matching therapies to your specific combination of blood counts, symptoms, and spleen size. The only potentially curative option is an allogeneic stem cell transplant, but most people are managed with medications that target symptoms and improve quality of life.
Risk Stratification Comes First
Before any treatment decisions, your hematologist will assign a risk score using a system called DIPSS Plus. This scoring tool combines clinical and genetic information to sort patients into four groups, each with very different survival outlooks. The four risk categories, with their median survival times, are: low risk (180 months), intermediate-1 (80 months), intermediate-2 (35 months), and high risk (16 months).
The score is built from several factors. Your baseline DIPSS score (which accounts for age, white blood cell count, hemoglobin, blood blasts, and constitutional symptoms like fevers and weight loss) provides the starting points. Then DIPSS Plus adds one point each for unfavorable chromosome changes, platelet counts below 100,000, and ongoing need for red blood cell transfusions. The total ranges from 0 to 6, and those points map directly to a risk group. This risk group shapes every subsequent decision, from whether you need a transplant evaluation to how aggressively symptoms should be treated.
Tracking Your Symptom Burden
Myelofibrosis can cause a wide range of symptoms that significantly affect daily life. A standardized tool called the MPN-SAF Total Symptom Score tracks ten specific problems: fatigue, difficulty concentrating, early satiety (feeling full after eating very little), inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Each is rated on a 0 to 10 scale.
This score matters because treatment choices often hinge on symptom severity rather than blood counts alone. Someone with a massively enlarged spleen and crushing fatigue needs a different approach than someone with the same risk score but minimal symptoms. Tracking these ten items over time also helps gauge whether a medication is actually working or needs to be changed.
JAK Inhibitors: The Core of Medical Therapy
Four JAK inhibitors are now available, and choosing between them comes down to your platelet count and anemia status. All of them work by blocking the overactive signaling pathway that drives the disease, but they differ in important ways.
Ruxolitinib is the most established option and typically the first choice for patients with adequate platelet counts. It is effective at shrinking the spleen and reducing constitutional symptoms like night sweats, fevers, and weight loss. The tradeoff is that it can worsen anemia and lower platelet counts, which limits its use in patients who are already struggling with low blood counts.
Fedratinib works through a similar mechanism and serves as an alternative when ruxolitinib stops working or isn’t tolerated. Like ruxolitinib, it can push hemoglobin lower and make anemia worse, so it carries the same limitations for patients with significant anemia.
Pacritinib fills a gap that the other drugs cannot. It is specifically approved for patients whose platelet counts have dropped below 50,000, a threshold that makes ruxolitinib and fedratinib too risky. For people with severe thrombocytopenia, pacritinib at 200 mg twice daily is the standard starting point. If platelet counts worsen significantly on treatment, the dose can be reduced or temporarily held until counts recover.
Momelotinib stands apart because of its effect on anemia. Unlike the other three JAK inhibitors, which tend to drop hemoglobin, momelotinib can stabilize or even improve anemia. This makes it the preferred option for patients who are already transfusion-dependent or whose anemia is the dominant problem. If your main challenge is needing regular blood transfusions alongside symptomatic spleen enlargement, momelotinib addresses both issues simultaneously.
Managing Anemia Beyond JAK Inhibitors
Anemia is one of the most common and debilitating features of myelofibrosis, and it often limits which other treatments you can tolerate. When JAK inhibitors alone aren’t enough, or when anemia is the primary issue, additional strategies come into play.
Luspatercept is a newer option that works by promoting red blood cell maturation. In clinical studies of myelofibrosis patients with transfusion-dependent anemia, about 26% achieved transfusion independence during the initial treatment period, and roughly 32% became transfusion-free when followed over the full course of treatment. It is given as a subcutaneous injection every three weeks, with doses gradually increased if the initial level doesn’t produce a sufficient response. While those response rates may sound modest, becoming free of regular transfusions represents a meaningful improvement in daily life.
Erythropoiesis-stimulating agents and danazol are older options that some patients still benefit from, particularly those with milder anemia. For patients with more severe transfusion needs, the focus shifts to momelotinib as a JAK inhibitor choice or luspatercept as an add-on therapy.
When Stem Cell Transplant Enters the Picture
Allogeneic stem cell transplant is the only treatment that can potentially eliminate myelofibrosis entirely. It involves replacing your bone marrow with healthy donor cells. However, it carries substantial risks, including graft-versus-host disease, infection, and treatment-related mortality, so it is reserved for patients whose disease outlook justifies those risks.
Transplant is generally considered for patients in the intermediate-2 or high-risk categories. These are patients with median survival times of 35 months or less without transplant. Medicare specifically covers transplant for these two groups when performed as part of an approved clinical study. Certain high-risk molecular mutations can also push the decision toward transplant even if the clinical risk score alone might not.
Age and overall fitness play a major role. Transplant outcomes are better in younger patients without significant organ damage, but reduced-intensity conditioning regimens have expanded eligibility to some older adults. If you fall into an intermediate-2 or high-risk group and are otherwise healthy enough, your hematologist will typically refer you for a transplant evaluation early, even if you’re responding to JAK inhibitor therapy. The evaluation process takes time, and having a donor identified in advance keeps the option available if your disease progresses.
Spleen-Directed Approaches
An enlarged spleen is one of the hallmark problems in myelofibrosis. It causes abdominal pain, early satiety, and can worsen blood counts by trapping and destroying blood cells. JAK inhibitors are the first-line treatment for symptomatic spleen enlargement, and most patients see meaningful spleen reduction within the first few months of therapy.
When medications fail to control spleen size, or when the spleen becomes massively enlarged and causes mechanical problems, splenectomy (surgical removal) or splenic radiation may be considered. Splenectomy in myelofibrosis carries higher risks than in other conditions because of abnormal blood counts and the potential for the liver to take over the spleen’s role in producing blood cells outside the bone marrow. It is typically a last resort when other options have been exhausted.
Putting the Pieces Together
In practice, treating myelofibrosis means reassessing regularly and adapting the plan as the disease evolves. A patient diagnosed at low risk with mild symptoms might be monitored without treatment for years. Someone at intermediate-1 risk with bothersome symptoms would typically start a JAK inhibitor chosen based on their platelet count and hemoglobin level. Patients at intermediate-2 or high risk get both a JAK inhibitor for symptom control and a transplant evaluation to determine whether curative therapy is feasible.
Throughout, anemia management runs as a parallel track. If a JAK inhibitor worsens anemia to the point of transfusion dependence, the options are switching to momelotinib, adding luspatercept, or adjusting doses. Symptom scores are rechecked periodically to measure whether the current regimen is delivering real improvement in the areas that matter most to daily life: fatigue, abdominal comfort, and the ability to stay active.